Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | USP19 | O94966 | 2/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.33 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4297253 | 0.97 | USP19 (0.33) | RENCYP3A4CHRM1USP19HCRTR1 | |
| SCHEMBL4290008 | 0.95 | REN (0.35) | RENCYP3A4CHRM1USP19HCRTR1 | |
| SCHEMBL4285530 | 0.85 | DRD2 (0.38) | CYP3A4HCRTR1HCRTR2DRD2DRD4 | |
| SCHEMBL4287530 | 0.84 | MAOA (0.37) | DRD2DRD4DRD3 | |
| SCHEMBL4288893 | 0.81 | USP19 (0.36) | RENUSP19HCRTR1HCRTR2 | |
| SCHEMBL4290897 | 0.81 | DRD2 (0.38) | CYP3A4USP19HCRTR1HCRTR2DRD2 | |
| SCHEMBL4285289 | 0.81 | HCRTR1 (0.38) | USP19HCRTR1HCRTR2AVPR1B | |
| SCHEMBL4285285 | 0.81 | KDM1A (0.35) | USP19HCRTR1HCRTR2AVPR1B | |
| SCHEMBL4289502 | 0.80 | DRD2 (0.38) | USP19HCRTR1HCRTR2DRD2DRD4 | |
| SCHEMBL4288589 | 0.80 | CPT1A (0.37) | USP19HCRTR1HCRTR2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | REN 1/4885CYP3A4 50/4885CHRM1 3125/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | REN 1/4885CYP3A4 50/4885CHRM1 3125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.